CAM
CPRX icon

Creekmur Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Creekmur Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-170
Closed -$2.86K – 854
2023
Q4 		$2.86K Buy
+170
New +$2.32K ﹤0.01% 655

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Creekmur Asset Management's CPRX Position: Q1 2024 in Review

Creekmur Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2024, closing a stake of 170 shares — an estimated $2.86K sold.

Creekmur Asset Management first reported a position in CPRX in Q4 2023 and held it in 1 quarter. The position peaked at $2.86K in Q4 2023. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

  • Creekmur Asset Management reported no remaining Catalyst Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Creekmur Asset Management sold 170 Catalyst Pharmaceutical shares in Q1 2024, an estimated $2.86K.
  • Creekmur Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 1 quarter.
  • Creekmur Asset Management's Catalyst Pharmaceutical position peaked at $2.86K in Q4 2023.
  • 269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Creekmur Asset Management's 13F filing for Q1 2024, filed 16 May 2024.